Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1262 | Favipiravir Wiki | 0.21 |
drug2448 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This is a protocol aimed at children and adolescents contaminated with COVID, treated at the Hospital das Clínicas, University of Sao Paulo, Brazil (HCFMUSP), in the recovery phase. The study aims to evaluate the spectrum of pathogenic lesions of the virus not only in the respiratory system, but digestive, immunological, neurological and others. Clinical, evolutionary, laboratory and functional parameters will be used.
Description: The instrument was translated and validated for the Brazilian population
Measure: Quality of Life assessed by the Pediatric Quality of Life Inventory (Peds-QoL) Time: Change from Baseline at 3 monthsDescription: The instrument was translated and validated for the Brazilian population
Measure: Quality of Life assessed by the Pediatric Quality of Life Inventory (Peds-QoL) Time: Change from Baseline at 6 monthsDescription: Aims to investigate the mechanisms that lead to dyspnea and, consequently, intolerance to physical effort
Measure: Flow-volume loop assessed by spirometry Time: Baseline, 3 months, 6 monthsDescription: It will also be assessed for school-age children (7-10 years old) and adolescents (11-18 years old) and by their primary caregiver
Measure: Health-related quality of life assessed by the Pediatric Outcomes Data Collection Instrument Time: Baseline, 3 months, 6 months, 12 monthsDescription: Patchy ground-glass opacities, crazy-paving pattern, and localization and pattern of large, confluent or small nodular lesions will be assessed
Measure: Lung abnormalities will be assessed by pulmonary computed tomography Time: Baseline, 3 months, 6 months, 12 monthsDescription: Conventional transthoracic echocardiogram with color Doppler to assess systolic and diastolic function
Measure: Systolic and diastolic function will be assessed by echocardiogram Time: Baseline, 3 months, 6 months, 12 monthsDescription: Conventional transthoracic echocardiogram with color Doppler to search for valve dysfunction
Measure: Valve dysfunction will be assessed by echocardiogram Time: Baseline, 3 months, 6 months, 12 monthsDescription: Conventional transthoracic echocardiogram with color Doppler to search for pericardial effusion
Measure: Pericardial effusion will be assessed by echocardiogram Time: Baseline, 3 months, 6 months, 12 monthsDescription: Conventional transthoracic echocardiogram with color Doppler to search for aspects of the coronary arteries
Measure: Coronary arteries will be assessed by echocardiogram Time: Baseline, 3 months, 6 months, 12 monthsDescription: Echocardiogram with two-dimensional speckle-tracking technique to identify subclinical changes suggestive of ischemia or myocarditis
Measure: Ischemia will be assessed by echocardiogram Time: Baseline, 3 months, 6 months, 12 monthsDescription: Baseline levels of cytokines IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-y, and IL-17A in serum samples will be tested by flow cytometry using the CBA technique (Cytometric bead array, BD Biosciences)
Measure: Immunocompetence, including thymic function Time: Baseline, 3 months, 6 months, 12 monthsDescription: T cell lineages: CD3CD4, CD3CD8, naive cells (CD45RA+), memory cells (CD45RA-), effector cells (CD38+HLADR+)
Measure: Immunophenotyping of lymphocytes T cell lineages will be evaluated by flow cytometry Time: Baseline, 3 months, 6 months, 12 monthsDescription: B cell lineages: CD19, naive cells (CD27-), memory cells (CD27+), plasmablasts (CD27+CD38+CD138-), (plasmocytes CD27+CD38+CD138+)
Measure: Immunophenotyping of lymphocytes B cell lineages will be evaluated by flow cytometry Time: Baseline, 3 months, 6 months, 12 monthsDescription: NK cells: (CD3-CD16+CD56+), degranulated: CD107a+
Measure: Immunophenotyping of lymphocytes NK cells will be evaluated by flow cytometry Time: Baseline, 3 months, 6 months, 12 monthsDescription: The antipneumococcal antibody titer against 6 polysaccharides (serotypes 1, 5, 6B, 9V, 14, and 18C) will be analyzed by ELISA. The seroconversion criteria is IgG values > 1.3 mg/mL for each polysaccharide assessed
Measure: Anti-pneumococcal vaccine response will be assessed by ELISA Time: Baseline, 3 months, 6 months, 12 monthsDescription: TRECs evaluate the peripheral function of the thymus from cells that have recently been released, using the RT-PCR technique
Measure: Evaluation of the thymus by the determination of TRECs (Thymic recent emigrant cells or T-cell receptor excision circles) Time: Baseline, 3 months, 6 months, 12 monthsDescription: (anti-thyroperoxidase antibodies, anti-thyroglobulin)
Measure: Changes in frequency of the autoantibodies of the thyroid gland Time: Baseline, 3 months, 6 months, 12 monthsDescription: According to the gene sequence studied, the analysis will be performed using the Sanger sequencing technique with capillary electrophoresis in a 3130 automatic sequencer (Applied Biosystems). The genetic polymorphisms of the ABO system gene (rs505922), two polymorphisms of the OPRM1 gene (rs1799971 and rs1799972) and a polymorphism of the BDNF gene (rs6265) will be investigated, with possible contributions to the risk of impaired gait.
Measure: Genetic Polymorphism Analysis will be assessed by salting out methodology followed by q-PCR (Real-time PCR) using the TaqMan assay using Step One Plus equipment Time: Baseline, 3 months, 6 months, 12 monthsDescription: This is an 18-item parent questionnaire for children and adolescents (18 years and younger). This rating scale includes positive "weaknesses" and negative "strengths" scoring, assessing symptoms of Attention-Deficit/Hyperactivity Disorder. Parents are asked to compare their child's behavior in a variety of settings over the past month to other children on a 7-point: 3-Far below, 2-Below, 1-Slightly below, 0-Average, -1-Slightly average, -2-Above, -3-Far above. Higher scores indicate greater symptomology
Measure: Mental health will be assessed by the "Strengths and Weaknesses of Attention-deficit/hyperactivity disorder (ADHD) symptoms and Normal behaviors" Time: Baseline, 3 months, 6 months, 12 monthsDescription: The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire, and includes 25 items on psychological attribute: emotional symptoms (5 items), conduct problems (5 items) hyperactivity/inattention (5 items), peer relationship problems (5 items), prosocial behaviour (5 items). Higher scores indicate greater difficulties
Measure: Mental health will be assessed by the "Strengths and Difficulties Questionnaire" Time: Baseline, 3 months, 6 months, 12 monthsDescription: The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress (7 items each subscale). Patients are asked to score every item on a scale from 0 (did not apply to me at all) to 3 (applied to me very much). Sum scores for the total DASS-total scale range between 0 and 120. Scores ≥60 (for DASS-total) and ≥21 (for the depression subscale) are labeled as "high" or "severe".
Measure: Mental health will be assessed by the "Depression, Anxiety and Stress Scale" Time: Baseline, 3 months, 6 months, 12 monthsDescription: ActivPAL will be used for 7 days for at least 10 hours/day
Measure: Physical activity levels assessed by ActivPAL Time: Baseline, 3 months, 6 months, 12 monthsDescription: 24-hour recalls will be assessed on three non-consecutive days (two weekdays, and one weekend). Online Dietbox will be used.
Measure: Food consumption levels assessed by food records Time: Baseline, 3 months, 6 months, 12 monthsDescription: Baseline blood flow measurements will be assessed in the brachial artery
Measure: Blood flow will be assessed using a Doppler Ultrasound Time: Baseline, 3 months, 6 months, 12 monthsDescription: Flow-mediated vasodilation (VMF) will be assessed in the brachial artery
Measure: Endothelial function will be assessed using a Doppler Ultrasound Time: Baseline, 3 months, 6 months, 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports